QOL Up With Pembrolizumab Versus Ipilimumab, HDI in Resected Melanoma

MONDAY, Nov. 28, 2022 -- For patients with high-risk resected melanoma, adjuvant pembrolizumab improves quality of life (QOL) compared with standard of care with ipilimumab or high-dose interferonα 2b (HDI), according to a study published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news